Matches in SemOpenAlex for { <https://semopenalex.org/work/W1749798840> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W1749798840 endingPage "304" @default.
- W1749798840 startingPage "297" @default.
- W1749798840 abstract "National adverse drug reaction registers in Sweden and the United Kingdom provided data on the type, severity and frequency of reported adverse reactions attributed to sulfa drugs. Reactions to the ten principal drugs were examined in terms of their half-lives and usual indications for use. Of 8339 reactions reported between 1968 and 1988, 1272 (15%) were blood dyscrasias, 3737 (45%) were skin disorders, and 578 (7%) involved the liver. These side-effects occurred with all types of sulfa drugs investigated, although at different relative rates, and 3525 (42%) of them were classified as serious. The overall case fatality rate (CFR) was 1:15 serious reactions, and was highest in patients with white blood cell dyscrasias (1:7). Drugs with longer elimination half-lives had higher CFRs, particularly for fatalities after skin reactions. In Sweden, the estimated incidences of serious reactions were between 9 and 33 per 100,000 short-term users of sulfa drugs (two weeks), between 53 and 111 among those on malaria prophylaxis, and between 1744 and 2031 in patients on continuous therapy. For dapsone, the incidence appeared to increase with higher doses. Our results indicate that sulfa drugs with short elimination half-lives deserve to be considered for use in combination with proguanil or chlorproguanil for malaria chemotherapy and possibly prophylaxis. The smaller risk of adverse reactions associated with lower-dose dapsone suggests that it should also be evaluated as a potentially safe alternative." @default.
- W1749798840 created "2016-06-24" @default.
- W1749798840 creator A5036853350 @default.
- W1749798840 creator A5063465178 @default.
- W1749798840 date "1991-01-01" @default.
- W1749798840 modified "2023-09-23" @default.
- W1749798840 title "Adverse reactions to sulfa drugs: implications for malaria chemotherapy." @default.
- W1749798840 cites W1916706013 @default.
- W1749798840 cites W1989490625 @default.
- W1749798840 cites W1995161323 @default.
- W1749798840 cites W2040099759 @default.
- W1749798840 cites W2101014303 @default.
- W1749798840 cites W2169510056 @default.
- W1749798840 cites W58415775 @default.
- W1749798840 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2393107" @default.
- W1749798840 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1893504" @default.
- W1749798840 hasPublicationYear "1991" @default.
- W1749798840 type Work @default.
- W1749798840 sameAs 1749798840 @default.
- W1749798840 citedByCount "25" @default.
- W1749798840 countsByYear W17497988402013 @default.
- W1749798840 countsByYear W17497988402014 @default.
- W1749798840 crossrefType "journal-article" @default.
- W1749798840 hasAuthorship W1749798840A5036853350 @default.
- W1749798840 hasAuthorship W1749798840A5063465178 @default.
- W1749798840 hasConcept C107130276 @default.
- W1749798840 hasConcept C113775271 @default.
- W1749798840 hasConcept C120665830 @default.
- W1749798840 hasConcept C121332964 @default.
- W1749798840 hasConcept C126322002 @default.
- W1749798840 hasConcept C141071460 @default.
- W1749798840 hasConcept C16005928 @default.
- W1749798840 hasConcept C187316915 @default.
- W1749798840 hasConcept C197934379 @default.
- W1749798840 hasConcept C203014093 @default.
- W1749798840 hasConcept C2776396001 @default.
- W1749798840 hasConcept C2777640609 @default.
- W1749798840 hasConcept C2778048844 @default.
- W1749798840 hasConcept C2780007613 @default.
- W1749798840 hasConcept C2780035454 @default.
- W1749798840 hasConcept C61511704 @default.
- W1749798840 hasConcept C71924100 @default.
- W1749798840 hasConcept C98274493 @default.
- W1749798840 hasConceptScore W1749798840C107130276 @default.
- W1749798840 hasConceptScore W1749798840C113775271 @default.
- W1749798840 hasConceptScore W1749798840C120665830 @default.
- W1749798840 hasConceptScore W1749798840C121332964 @default.
- W1749798840 hasConceptScore W1749798840C126322002 @default.
- W1749798840 hasConceptScore W1749798840C141071460 @default.
- W1749798840 hasConceptScore W1749798840C16005928 @default.
- W1749798840 hasConceptScore W1749798840C187316915 @default.
- W1749798840 hasConceptScore W1749798840C197934379 @default.
- W1749798840 hasConceptScore W1749798840C203014093 @default.
- W1749798840 hasConceptScore W1749798840C2776396001 @default.
- W1749798840 hasConceptScore W1749798840C2777640609 @default.
- W1749798840 hasConceptScore W1749798840C2778048844 @default.
- W1749798840 hasConceptScore W1749798840C2780007613 @default.
- W1749798840 hasConceptScore W1749798840C2780035454 @default.
- W1749798840 hasConceptScore W1749798840C61511704 @default.
- W1749798840 hasConceptScore W1749798840C71924100 @default.
- W1749798840 hasConceptScore W1749798840C98274493 @default.
- W1749798840 hasIssue "3" @default.
- W1749798840 hasLocation W17497988401 @default.
- W1749798840 hasOpenAccess W1749798840 @default.
- W1749798840 hasPrimaryLocation W17497988401 @default.
- W1749798840 hasRelatedWork W1749798840 @default.
- W1749798840 hasRelatedWork W2003938723 @default.
- W1749798840 hasRelatedWork W2019517015 @default.
- W1749798840 hasRelatedWork W2118496982 @default.
- W1749798840 hasRelatedWork W2364998975 @default.
- W1749798840 hasRelatedWork W2369162477 @default.
- W1749798840 hasRelatedWork W2439875401 @default.
- W1749798840 hasRelatedWork W4238867864 @default.
- W1749798840 hasRelatedWork W2519357708 @default.
- W1749798840 hasRelatedWork W2525756941 @default.
- W1749798840 hasVolume "69" @default.
- W1749798840 isParatext "false" @default.
- W1749798840 isRetracted "false" @default.
- W1749798840 magId "1749798840" @default.
- W1749798840 workType "article" @default.